The World Molecular Imaging Society (WMIS) is collaborating with the U.S. National Cancer Institute (NCI) to promote best practices for co-clinical trials.
The goal of the partnership is to speed the discovery of more and better treatments for cancer and other diseases, WMIS said. The initiative is also designed to help establish best practices for quantitative imaging methods and imaging protocols that are applied to both mouse and human-in-mouse models.
Co-clinical trials are parallel or sequential clinical trials of combination therapy in patients and in mouse and human-in-mouse models to represent patients. The new initiative is intended to help set up best practices for quantitative imaging methods and imaging protocols that can be applied to both mouse and human-in-mouse models.
Over the past two years, WMIS and the American Association of Physicists in Medicine (AAPM) have shared their interest with NCI to promote best practices for co-clinical trials.
As part of the agreement, WMIS will include two spotlight sessions on precision medicine and co-clinical trials during the upcoming World Molecular Imaging Congress in September in Honolulu.
